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Independent Review of Interstitial Lung Disease Associated
with Death in TRIBUTE (Paclitaxel and Carboplatin with or
without Concurrent Erlotinib) in Advanced Non-small Cell
Lung Cancer
Ken Y. Yoneda, MD,* David K. Shelton, MD,† Laurel A. Beckett, PhD,‡ and David R. Gandara, MD§
Introduction: A rare but serious complication of epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is a
lung injury syndrome commonly referred to as a drug-induced
interstitial lung disease (ILD). It has a typical clinical presentation of
rapidly progressive acute or subacute dyspnea and a histopathology
of diffuse alveolar damage (DAD). The incidence, severity, and risk
factors for EGFR TKI-induced ILD remain poorly understood.
Whether concurrent chemotherapy increases its risk is also unclear.
The primary focus of this blinded review was to determine the
incidence of ILD leading to death in 1059 TRIBUTE patients
randomized to chemotherapy plus erlotinib or placebo.
Methods: All fatal serious adverse events (SAEs) were reviewed by
an independent three-person panel composed of a medical oncolo-
gist, radiologist, and pulmonologist not associated with the study
and without knowledge of treatment assignment. Fatal respiratory
SAEs were identified and assigned to one of four potential attribu-
tions: progressive cancer, concurrent illness, drug-induced ILD, or
other toxicities not related to ILD. Each panel member first made an
independent assignation; then each case was discussed jointly. If
needed, consensus was reached by vote.
Results: Fatal SAEs were reported in 80 of 1059 patients (7.6%): 53
of 526 patients on erlotinib (10.1%) and 27 of 533 on placebo
(5.1%) (p  0.05). Consensus assignation for 41 fatal respiratory
SAEs was as follows: cancer, 18 (44%); concurrent illness, 15
(37%); other toxicities not related to ILD, five (12%); ILD, three
(7%). All three ILD cases occurred in the erlotinib arm (3/526;
0.6%). The one biopsy-confirmed case of ILD revealed bronchiolitis
obliterans organizing pneumonia, a histopathologic finding that has
not previously been reported. All three cases of fatal ILD had a
typical clinical presentation of acute or subacute onset of dyspnea
with rapid progression to respiratory failure.
Conclusions: This independent blinded analysis of the TRIBUTE
study identified fatal ILD in 0.6% of cases treated with the combi-
nation of erlotinib plus chemotherapy, possibly higher than previous
reports of EGFR TKIs alone in the non-Japanese population. Fatal
ILD alone does not fully account for the imbalance in fatal SAEs
observed in TRIBUTE. EGFR TKI-induced fatal ILD typically
presents with acute or subacute dyspnea with rapid progression and
a typical histopathology of diffuse alveolar damage both consistent
with the acute respiratory distress syndrome, but can also be asso-
ciated with a histopathology of bronchiolitis obliterans organizing
pneumonia. Further studies designed to better understand the under-
lying pathophysiology and risk factors for ILD are needed.
Key Words: Erlotinib, Tarceva, Epidermal growth factor receptor,
tyrosine kinase inhibitor, non-small cell lung cancer, interstitial lung
disease, acute respiratory distress syndrome, TRIBUTE.
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A drug-induced lung injury syndrome has been well doc-umented in association with the use of epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in
the treatment of non-small cell lung cancer (NSCLC). As a
recently described and rare syndrome, its pathophysiology,
incidence, severity, and risk factors for development remain
poorly understood. Although its histopathology has been
incompletely characterized, it has generally been referred to
as a drug-induced interstitial lung disease (ILD). Its clinical
manifestations appear to be unique, with patients presenting
with a delayed then rapidly progressive, acute, or subacute
dyspnea, invariably requiring hospitalization. Respiratory
failure is common, and the disorder is fatal in one third of
cases. Given the recent approval of erlotinib (Tarceva; Roche,
Basel, Switzerland/Genentech, San Francisco, CA) for the
use in second-line treatment of NSCLC, there is justified
interest in this disorder and other potential toxicities with
these agents. In this regard and in an effort to further char-
acterize the clinical and pathophysiologic characteristics of
EGFR TKI-induced fatal ILD and the potential effects of
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concurrent chemotherapy, the TRIBUTE study was indepen-
dently reviewed.
Lung cancer is the leading cause of cancer death in the
United States, where it accounts for more deaths than colon,
breast, and prostate cancer combined. Although recent im-
provements in chemotherapy for advanced stage NSCLC are
well documented, the survival impact of this therapeutic
approach remains limited, and chemotherapy is still associ-
ated with considerable side effects. Therefore, novel ap-
proaches to the treatment of NSCLC are the focus of intense
basic science and clinical research interest. Recent advances
in understanding the underlying molecular biology of lung
cancer have facilitated development of new therapies directed
against gene targets important in NSCLC growth and survival
pathways. For example, EGFR, a member of the HER or
Erb-B family of receptor TKs, is implicated in the develop-
ment and progression of cancer and is expressed in many
human malignancies, including NSCLC.1–3 Small molecule
TKIs of EGFR, such as gefitinib (Iressa, AstraZeneca, Lon-
don, UK) and erlotinib (Tarceva) have demonstrated anti-
tumor activity against NSCLC in preclinical models and
response rates of 9% to 26% in patients failing initial che-
motherapy.4–6 Moreover, a recent phase III trial (BR21)
comparing erlotinib with placebo as second- or third-line
therapy reported a survival benefit for the EGFR TKI.7
Conversely, ISEL, a placebo controlled phase III trial for
refractory NSCLC, failed to demonstrate a survival advan-
tage for gefitinib,8 and phase III trials of chemotherapy with
or without concurrent gefitinib (INTACT 1 and INTACT 2)
or erlotinib (TRIBUTE and TALENT) showed no benefit in
response rate or survival with the addition of the EGFR TKIs
and in fact suggest a negative interaction.9–12
Although generally well tolerated, EGFR TKIs have
been associated with the development of severe or fatal
ILD.13 EGFR TKI-induced ILD presents at approximately 24
and 42 days after starting gefitinib in Japanese and the
non-Japanese populations, respectively,14 and approximately
47 days after starting erlotinib.15 It is characterized by the
acute or subacute onset of dyspnea with or without cough or
low-grade fever, rapid progression requiring hospitalization,
and often respiratory failure requiring mechanical ventilation.
Chest radiographs and high-resolution computed tomography
(CT) reveal bilateral opacifications, often resembling acute
interstitial pneumonitis, but the radiographic findings are
variable and nonspecific.16,17 Although referred to as an ILD
syndrome, the histopathology has been incompletely charac-
terized, revealing diffuse alveolar damage, consistent with the
acute respiratory distress syndrome (ARDS). Nevertheless,
pathologic confirmation is rarely obtained, and the syndrome
has been characterized mainly on clinical grounds.
Whether the two EGFR TKIs differ in the propensity to
induce ILD is unclear. Furthermore, whether concurrent che-
motherapy increases toxicities such as ILD has not been
specifically assessed. In this regard, in TRIBUTE, more
serious adverse events (SAEs) leading to death were reported
in patients on the erlotinib arm.11 Such events were experi-
enced by 53 of 526 patients in the erlotinib arm (10.1%) and
27 of 533 patients in the placebo arm (5.1%), p  0.05.
In light of the imbalance in fatal SAEs observed in the
TRIBUTE study (with fatal ILD as a potential explanation),
a blinded review of SAEs leading to death in TRIBUTE was
performed. An independent three-person panel, the TRIB-
UTE review committee (TRC) focused this review on fatal
respiratory SAEs. Fatal respiratory SAEs were attributed to
the following categories: ILD, progression of underlying
NSCLC, concurrent illness, or other toxicities not related
to ILD. The primary focus of this study was to determine
the incidence of fatal ILD in patients treated for NSCLC
with chemotherapy plus erlotinib or placebo and to esti-
mate whether chemotherapy increased the risk of erlotinib-
induced ILD.
METHODS
Details of the TRIBUTE study are as previously de-
scribed.11 Adverse events had been previously coded by the
original TRIBUTE investigators using the Medical Dictio-
nary for Regulatory Activities (MedDRA), Version 6.0. Event
severity was graded using the National Cancer Institute–
Common Toxicity Criteria (NCI-CTC), Version 2.0. All
cases that had been previously coded as fatal SAEs by the
TRIBUTE investigators were forwarded to the TRC. The
TRC consisted of three physicians (a medical oncologist, a
pulmonologist, and a thoracic radiologist) not associated with
TRIBUTE.
For the current analysis, all fatal SAEs from both study
arms of TRIBUTE were reviewed. Fatal SAEs that had been
coded by the original TRIBUTE investigators to the Med-
DRA system organ class (SOC) as respiratory were classified
as respiratory-related fatal SAEs and identified for further
review by the TRC. Additionally, fatal SAEs coded by the
TRIBUTE investigators as being associated with pneumonia
(which appears in the MedDRA SOC of Infections and
infestations) and neoplasm were also classified as respiratory-
related fatal SAEs and identified for further review by the
TRC. All other fatal SAEs deemed not related to a respiratory
event were not subject to further review by the TRC.
The three TRC members, blinded to study arm and
whether patients under review had been randomized to erlo-
tinib or placebo, independently assessed and assigned causal-
ity for each case of fatal SAE under investigation, using the
case report forms and source documents available to the
original TRIBUTE investigators.11 Baseline patient charac-
teristics in regards to preexisting ILD, asbestos exposure, and
pulmonary function tests were not specifically recorded as a
part of the study protocol but were noted as available from the
source documents. Fatal SAEs were first categorized as due
to either progression of NSCLC or to an unexpected SAE.
The unexpected fatal SAEs were then subclassified as due to
either ILD possibly/probably related to study drug, concur-
rent illness, or other toxicities not thought to be related to
ILD. For the assignation of ILD, four specific findings were
required: (1) progressive dyspnea with or without cough or
fever, (2) lack of evidence of infection, (3) radiographic
findings consistent with drug-induced ILD (i.e., bilateral,
diffuse, or patchy interstitial and/or alveolar opacifications
without evidence of marked progression of underlying lung
Yoneda et al. Journal of Thoracic Oncology • Volume 2, Number 6, June 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer538
cancer), and (4) consistent pathologic findings if available.
These criteria were designed with the intention of being more
specific than sensitive for identifying a drug-induced phe-
nomenon. After individual assessment by each TRC member,
the team then met to determine consensus assignations.
Where there was not initial unanimous consensus, the TRC
revisited the case as a group to formalize consensus. When
deemed necessary, additional information such as additional
radiographs, laboratory data, and medical records were re-
quested. If a unanimous consensus assignation was not
reached after completion of this process, the final determina-
tion of causality was based on a majority vote.
RESULTS
Of a total of 80 fatal SAEs, 22 were respiratory as
coded according to the MedDRA SOC and were identified for
TRC review. Additionally, 12 fatal SAEs associated with
pneumonia and seven cases attributed to neoplasm were
identified for additional review. In total, there were 41 cases
identified as SAEs potentially due to respiratory events.
Nonrespiratory fatal SAEs not subject to further review
consisted of acute myocardial infarction (n  7), acute
cardiac or cardiopulmonary arrest (n  5), cerebral vascular
accident (n  4), sepsis or septic shock (n  4), dehydration
(n  2), asthenia (n  2), intestinal perforation (n  2),
arrhythmia (n  2), intestinal ischemia (n  1), deep vein
thrombosis (n  1), cardiac tamponade (n  1), pericardial
effusion (n  1), congestive heart failure (n  1), superior
vena cava occlusion (n  1), gastrointestinal hemorrhage
(n  1), diarrhea (n  1), thrombocytopenia (n  1), aortic
aneurysm rupture (n  1), and mental status change (n  1).
Of 41 respiratory fatal SAEs reviewed (Figure 1), by
consensus assignation, 18 were definitively attributed to pro-
gression of NSCLC, leaving 23 unexpected SAEs. Of the 23
unexpected SAEs, 15 were definitively attributed to concur-
rent illness (e.g., progression of a preexisting disorder) and
five to toxicity other than ILD (e.g., neutropenia with sepsis).
In one of the 15 cases of concurrent illness, the TRC believed
the fatal SAE to be due to progression of bronchiolitis
obliterans organizing pneumonia (BOOP) with fibrosis, but
not attributable to study drug as the patient had biopsy-proven
BOOP and fibrosis with symptomatic and radiographic pro-
gression requiring escalating doses of systemic corticoste-
roids just before beginning study drug. In three cases, the
investigators determined that the fatal SAE was due to ILD
and possibly/probably related to study drug. With unblinding,
it was apparent that all three cases of fatal ILD occurred in the
erlotinib arm. There were no cases of fatal ILD identified in
the chemotherapy alone arm. These results represent a rate of
fatal ILD of 0.6% (3/526) in association with the use of
erlotinib and concurrent chemotherapy in this trial.
The three cases of ILD attributed to study drug are
briefly presented below and summarized in Table 1. After
review of the chest CT scans and other source documents by
the TRC, the consensus was that the findings in each case
were most consistent with ILD and not with progressive
cancer or infection.
Case 1
The patient was a 56-year-old African American male,
active smoker, with stage IV adenocarcinoma. Thirteen days
after beginning study drug at 100 mg, chest radiography and
CT scan performed to evaluate increasing dyspnea revealed
new extensive interstitial infiltrates throughout the majority
of the right lung and mild interstitial infiltrates at the left base.
He was treated with intravenous corticosteroids and intrave-
nous antibiotics empirically for an exacerbation of underlying
chronic obstructive pulmonary disease (COPD) and infection.
A bronchoscopy with bronchoalveolar lavage (BAL) was
negative for pathogens. Twenty-eight days after beginning
study drug and while continuously maintained on intravenous
corticosteroids, the dose was increased to 150 mg, per pro-
tocol specifications. Twenty-nine days after starting study
drug, a repeat CT scan noted extensive bilateral interstitial
and alveolar infiltrates. Forty days after beginning study drug,
the patient died and the original TRIBUTE investigator had
reported his death as due to progressive NSCLC. Neither lung
biopsy nor autopsy was performed.
Case 2
The patient was a 70-year-old white woman, former
smoker, with bronchioloalveolar cell lung cancer. Serial chest
CT scans while on study revealed a progressive bilateral
alveolar filling process consistent with either bronchioloal-
veolar carcinoma or pneumonitis; 124 days after beginning
study drug and 1 day after her fifth cycle of chemotherapy,
she was hospitalized with fever, dyspnea, and dramatically
worsening bilateral alveolar and interstitial opacifications on
chest radiography and CT compared with baseline (Figure 2).
Her white blood count was not elevated from baseline and
cultures were negative. Empiric systemic corticosteroids
were started. She died 4 days later, despite aggressive sup-
portive care. Neither lung biopsy nor autopsy was performed.
FIGURE 1. Distribution of severe adverse events (SAEs) as-
sociated with death. In a blinded fashion, the Tribute Review
Committee identified 41 of 80 fatal SAEs to be respiratory
related and 18 of these 41 to be due to progressive lung
cancer. The remaining 23 were assigned to either concur-
rent illness (n 15) or other toxicity not related to interstitial
lung disease (ILD). ILD possibly related to study drug was
identified in three patients.
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Case 3
The patient was a 43-year-old African American
woman, recent ex-smoker, with stage IIIB NSCLC with a
right-sided malignant pleural effusion. Before starting on
study drug, she was noted to have right-sided lung nodules
and ground-glass opacifications in the left upper and lower
lobes. Five days after starting study drug, the patient was
hospitalized with hypoxemia, dyspnea, fever, chest pain, and
a worsening chest CT. There was no improvement with
empirical intravenous antibiotics. Bronchoscopy with BAL
was negative for pathogens. With progressive decline, 20
days after starting study drug, a surgical biopsy revealed
BOOP without evidence of infection. Study drug was discon-
tinued at day 23 and high-dose systemic corticosteroids were
started. The patient had symptomatic improvement and was
discharged home on oxygen on day 36, but was rehospi-
talized with increasing dyspnea. With progressive respira-
tory failure, she was placed under hospice care and died on
day 51.
DISCUSSION
The EGFR TKIs erlotinib and gefitinib are active anti-
cancer agents in the treatment of patients with NSCLC and
are generally well tolerated. In the recent BR21 trial, erlotinib
improved survival compared with placebo in chemotherapy-
pretreated patients with advanced stage NSCLC.7 Although
ISEL, a similar trial with gefitinib, failed to demonstrate a
survival advantage, subgroup analysis of this study suggested
a survival benefit for never smokers and Asian patients who
received gefitinib.8 Conversely, four large phase III trials in
TABLE 1. Characteristics of the Three Patients with ILD Attributed to Study Drug
Patient Age (yr) Race/Ethnicity
Smoking
Status
NSCLC
Subtype Stage
Results of
CT Scan Clinical Symptoms
No. of Days
in Study at Death
1 56 African
American
Active Adenoca IV ILD with mixed
interstitial and
airspace
opacities
Increasing dyspnea 40
2 70 White Former smoker BAC IV Progressive
alveolar filling
Fever, dyspnea 128
3 43 African
American
Recent
ex-smoker
NSCLC IIIB (pleural
effusion)
ILD Hypoxemia, dyspnea,
chest pain
51
Adenoca, adenocarcinoma; BAC, bronchioloalveolar carcinoma; CT, computed tomography; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer.
FIGURE 2. (A) Chest radiograph at base-
line (case 2). (B) Chest radiograph at the
time of respiratory decompensation. (C)
Computed tomography scan at the time
of respiratory decompensation (case 2).
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the first-line therapy of advanced NSCLC comparing chemo-
therapy alone to the concurrent administration with either
gefitinib or erlotinib showed no advantage for the combina-
tions and in fact suggest a negative interaction.9–12,18 Possible
explanations for these negative results include failure to
select for an EGFR-targeted population, a negative interac-
tion between EGFR TKIs and chemotherapy, and additive
toxicities.19 An increased incidence of fatal SAEs in TRIB-
UTE for patients in the combination arm is particularly
concerning for additive toxicities as a cause of increased
mortality. In this review, we focused on fatal ILD as a
potential cause of the imbalance in fatal SAEs observed in
TRIBUTE.
EGFR TKI-induced ILD has been most extensively
described in regards to gefitinib. In two different randomized
phase II trials, ILD was reported in 0.47% (2/425) of patients,
with both cases occurring at the 500-mg dose.4,5 In INTACT
1 and INTACT 2 combining gefitinib with standard first-line
chemotherapy for advanced NSCLC, ILD was reported in
0.86% of patients receiving placebo, 1.14% of patients re-
ceiving 250 mg gefitinib, and 1.14% of patients receiving 500
mg gefitinib.9,10 A report by the U.S. Food and Drug Admin-
istration of 50,005 patients receiving gefitinib (18,960 from
Japan and 23,000 from the United States) revealed an overall
incidence of ILD of approximately 1%. Interestingly, in
Japanese patients, the incidence was 1.7%, whereas in U.S.
patients, it was 0.3%. The median time to onset of ILD was
24 days in Japan and 42 days in the United States. Approx-
imately one third of cases were fatal.14 A safety report by
AstraZeneca, the makers of gefitinib, on approximately
185,000 patients revealed similar findings.20 The ISEL trial
revealed a higher incidence of ILD in Japanese patients
compared with non-Japanese patients (3%–4% versus 1%).8
Most recently, the West Japan Thoracic Oncology Group
convened an expert panel review of 1976 consecutive patients
treated with gefitinib, specifically focusing on the develop-
ment of ILD. They found an incidence of 3.5% with an
attributed mortality of 1.6%. Male sex, a smoking history,
and concurrent interstitial pneumonia were identified as in-
dependent risk factors for the development of ILD.21
The incidence of ILD associated with erlotinib is less
well defined. Limited data from phase I clinical trials with a
total of 157 patients reported no recognized cases of ILD, but
one patient reportedly died of undefined lung toxicity.6,22,23 In
the BR21 trial, in which erlotinib was compared with pla-
cebo, the term ILD was not used, but the overall incidence of
pulmonary fibrosis plus pneumonitis was reported to be 6% in
each arm. One death from pneumonitis was observed in each
study arm, resulting in an incidence of 0.2% for erlotinib and
0.4% for placebo.7 The recently published TRIBUTE trial
reported a 1% (5/526) incidence of ILD in the erlotinib plus
chemotherapy arm and a 0.2% (1/533) incidence in the
placebo plus chemotherapy arm. All reported cases of ILD
were fatal. However, reports of ILD were based on case
reporting of adverse events and not systematically verified by
an independent blinded panel as in our review of these data.11
Establishing a diagnosis of ILD is often difficult and is
particularly challenging in the absence of a confirmatory
surgical lung biopsy. Even with a surgical lung biopsy,
assigning causality remains a difficult challenge. Chemother-
apy and radiotherapy, either alone or in combination, have
been associated with the development of ILD. Of reported
cases of ILD in association with gefitinib use, 31% of patients
had received previous radiation therapy and 57% had re-
ceived previous chemotherapy.14 In INTACT 1 and 2 com-
bined, the overall incidence of ILD was 1.14% with gefitinib
plus chemotherapy. In addition, infections, medications, and
other environmental exposures can mimic ILD or potentially
increase the susceptibility to ILD. As demonstrated in the
current analysis, it may sometimes be difficult to distinguish
progressive cancer, particularly of the bronchioloalveolar
subtype, from EGFR TKI-induced ILD. Accordingly, in this
study, particular care was taken in assigning a diagnosis of
ILD. All suspected cases of fatal ILD were meticulously
reviewed by an independent expert panel consisting of a
medical oncologist, a pulmonologist, and a thoracic radiolo-
gist, who performed a thorough and detailed review of the
clinical history and radiographic findings.
Our study focused on identifying fatal cases of ILD,
derived as a subset of fatal SAEs identified in TRIBUTE. If
ILD due to erlotinib is fatal in approximately one third of
cases, as previously described for gefitinib, then we estimate
that the overall incidence of ILD was approximately 1.8% in
patients receiving the combination of chemotherapy plus
erlotinib in TRIBUTE. Unfortunately, the retrospective na-
ture of this analysis, the variability in radiographic presenta-
tion, and the paucity of pathologic confirmation confound our
ability to draw firm conclusions. Underscoring these uncer-
tainties, it is reported that findings on CT scanning correlate
with histopathology in less than 60% of cases of drug-
induced ILD.24 Of interest is one patient in our study
(classified as concurrent illness and not ILD) who had
biopsy-proven ILD before enrolling in TRIBUTE and who
developed worsening and eventually fatal ILD in the erlo-
tinib-chemotherapy arm. As described above, the West Japan
Thoracic Oncology Group reported concurrent interstitial
pneumonia as a risk factor for the development of gefitinib-
induced ILD. In addition, among a case series of 110 patients
treated with gefitinib in Japan were nine patients with preex-
isting pulmonary fibrosis. Five of the nine patients developed
acute lung injury during treatment, and of those, three died.13
A retrospective analysis of 12 patients with gefitinib-induced
ILD and preexisting idiopathic pulmonary fibrosis also sug-
gests a high mortality rate of 58%.16
Although a variety of medications and chemotherapeu-
tic agents have been implicated in the development of ILD,
EGFR TKI–induced ILD may represent a unique clinical
syndrome. ILD attributed to EGFR TKIs has been described
as an acute lung injury syndrome (ALI), an acute respiratory
distress syndrome (ARDS), pneumonitis, interstitial pneumo-
nia, interstitial fibrosis, drug-induced pulmonary toxicity, and
alveolar hemorrhage, but the clinical presentations are invari-
ably similar. Typical pulmonary symptoms are acute onset of
dyspnea with or without cough or low-grade fever, followed
by a rapid worsening of symptoms invariably requiring hos-
pitalization.14 In a retrospective analysis of gefitinib-induced
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ILD, the median time to onset was 24 to 31 days for patients
in Japan and 42 days for patients in the United States.21,25
ILD with erlotinib occurred as early as 5 days to more than 9
months after initiation of treatment (median time to occur-
rence, 47 days).14 All three of our cases of fatal ILD are
consistent with this clinical description.
To our knowledge, case 3 is the first time that the
histopathology of BOOP has been reported in association
with EGFR TKI use. Apart from one case of alveolar hem-
orrhage diagnosed by bronchoscopy,26 published reports on
the histopathology of EGFR TKI-induced ILD, invariably
reveal DAD based on open lung biopsy or autopsy.27 Apart
from our case of BOOP, the lung histology, and the clinical
manifestations of EGFR TKI–induced ILD are very similar to
ALI/ARDS associated with the broadly defined systemic
inflammatory response syndrome.21,28,29 In addition, the West
Japan Thoracic Oncology Group has described four differ-
ent patterns of gefitinib-induced ILD including nonspecific
ground-glass attenuation (47% of cases), extensive bilateral
ground-glass attenuation or airspace consolidations with trac-
tion bronchiectasis (24%), multifocal airspace consolidations
(14%), and patchy distribution of ground-glass attenuation
with interlobar septal thickening (2%), all of which are
consistent with radiographic patterns of ARDS.17
Treatment of EGFR TKI–induced ILD is largely sup-
portive, including supplemental oxygen, empirical antibiot-
ics, and mechanical ventilation. Immediate discontinuation of
the drug is recommended and systemic corticosteroids are
usually prescribed, although no controlled trials have been
conducted to evaluate their benefit. Approximately one third
of the patients with EGFR TKI–induced ILD die. The clinical
course, radiographic findings, lung pathology, and mortality
of EGFR TKI–induced ILD is most consistent with ALI/
ARDS and with the exception of empirical corticosteroids,
the treatment is identical. EGFR TKI–induced ILD should
therefore be considered in the differential diagnosis as a
potential cause of ARDS in any patient who is on an EGFR
TKI who presents with acute or subacute dyspnea.30
CONCLUSION
In this blinded review of the TRIBUTE trial, the inci-
dence of fatal ILD in association with the administration of
erlotinib and concurrent paclitaxel and carboplatin was de-
termined to be 0.6%, with an overall incidence estimated at
approximately 1.8%. Given the uncertainties in diagnosing
and assigning causality to ILD, these results may be higher
than those previously reported in association with gefitinib
alone in the non-Japanese population. The possibility of a
synergistic effect between chemotherapy and EGFR TKIs in
the development of ILD cannot be ruled out. The histopatho-
logic finding in EGFR TKI–induced ILD is invariably DAD,
although we report a case with BOOP. Patients receiving
EGFR TKIs, particularly those with preexisting pulmonary
fibrosis or a diagnosis of underlying ILD, should be moni-
tored closely for development or worsening of ILD. EGFR
TKI–induced ILD has a high associated mortality, and when
it is suspected, the drug should immediately be withdrawn,
hospitalization and systemic corticosteroids considered, and
infection ruled out. EGFR TKI–induced ILD should be con-
sidered as a potential cause of ALI/ARDS and the manage-
ment of these patients should therefore be consistent with
contemporary ALI/ARDS management.
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